Ouro Medicines
Latest round
- Series A
Last raised
- Jan 2025
Total raised
- $120M
Investors
- 8
About Ouro Medicines
Founded in 2025 and based in California, US, Ouro Medicines, Inc. specializes in creating therapeutics for immune-mediated diseases. In March 2026, Gilead Sciences, Inc. a portfolio company of Third Rock Ventures, Casdin Capital, and Cormorant Asset Management agreed to fully acquire Ouro Medicines, Inc.68 billion and will receive additional payment of USD 500 million upon achieving milestones. Ouro Medicines specializes in developing therapeutics aimed at resetting the immune system, focusing primarily on chronic immune-mediated diseases. The company’s core product is the lead therapeutic candidate, OM336, which utilizes T cell engagers (TCEs) to deplete proinflammatory cells. TCEs serve as an off-the-shelf therapeutic modality designed to induce an immunological 'reset,' potentially allowing for durable remissions without ongoing immunosuppression. Additionally, Ouro Medicines is advancing several discovery programs targeting unique subsets of B cells to facilitate longer remissions for certain diseases. The company operates a revenue model primarily driven by partnerships and collaborations with biopharmaceutical companies for the development and commercialization of its therapeutics. Revenue generation is expected through licensing agreements and milestone payments associated with their lead candidate, OM336, and other products in their pipeline.
Who invested in Ouro Medicines
8 investors across 1 round
See all investors in Ouro Medicines
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jan 10, 2025
Amount
$120M
Investors
Questions about Ouro Medicines
Who invested in Ouro Medicines?
Ouro Medicines has 8 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ouro Medicines raised?
Ouro Medicines has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Ouro Medicines last raise money?
Ouro Medicines's most recent round on record is a Series A, in Jan 2025.
What does Ouro Medicines do?
Founded in 2025 and based in California, US, Ouro Medicines, Inc.
Where is Ouro Medicines headquartered?
Ouro Medicines is headquartered in South San Francisco, US.
Which VCs invest in companies like Ouro Medicines?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Ouro Medicines's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Ouro Medicines? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.